Search
Narcolepsy Paid Clinical Trials in Ohio
A listing of 6 Narcolepsy clinical trials in Ohio actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 6 of 6
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Narcolepsy
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Ohio currently has 6 active clinical trials seeking participants for Narcolepsy research studies. These trials are conducted in various cities, including Cincinnati, Columbus, Cleveland and Dayton.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Narcolepsy Clinical Study
Recruiting
The Vibrance Studies are researching the safety and effectiveness of a once-daily oral investigational study drug and how it may work in adults 18–70 years of age for the potential treatment of excessive daytime sleepiness (EDS) symptoms in adults with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2).
All participants who qualify will receive the study drug or placebo (a tablet that looks like the study drug but contains no active medicine), as well as study-related procedures and study-related laboratory tests at no cost. Compensation for time and travel may also be available.
All participants who qualify will receive the study drug or placebo (a tablet that looks like the study drug but contains no active medicine), as well as study-related procedures and study-related laboratory tests at no cost. Compensation for time and travel may also be available.
Conditions:
Narcolepsy
Narcolepsy With Cataplexy
Narcolepsy Without Cataplexy
Narcolepsy 1
Narcolepsy Type 1
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects with Narcolepsy Type 1 (ALKS 2680-201)
Recruiting
The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/10/2025
Locations: Alkermes Investigator Site, Canton, Ohio +3 locations
Conditions: Narcolepsy Type 1
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects with Narcolepsy Type 2
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/05/2025
Locations: Alkermes Investigator Site, Canton, Ohio +2 locations
Conditions: Narcolepsy Type 2
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy
Recruiting
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/06/2025
Locations: Alkermes Investigational Site, Cincinnati, Ohio
Conditions: Narcolepsy Type 1, Narcolepsy Type 2
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Recruiting
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
09/24/2024
Locations: CTI Research Center, Cincinnati, Ohio +3 locations
Conditions: Narcolepsy Type 1
Child and Adolescent Registry for Participants With Narcolepsy
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed.
The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
08/13/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +3 locations
Conditions: Narcolepsy
Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy
Recruiting
This study intends to examine the utility of a home-use EEG-based sleep monitor for the diagnosis and evaluation of disorders of excessive sleepiness, specifically the neurological disorder Narcolepsy Type 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Intrepid Research, Cincinnati, Ohio
Conditions: Narcolepsy Type 1, Hypersomnia, Sleep Disorder
1 - 6 of 6